GLP-1 drugs linked to higher fracture risk, osteoporosis and gout, new studies suggest
New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.
Could GLP-1 drugs cut the risk of complications after a heart attack?
How do GLP-1 agonists affect gene expression?
GLP-1s are building a reputation as “wonder drugs.” First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health. In addition to these surprising bonus benefits is the ability of GLP-1 drugs to improve pancreatic beta cell health. But how, exactly, are they doing that?
STAT+: Novo Nordisk’s Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds
Generic versions of Novo Nordisk’s Wegovy and Ozempic medications could be mass produced for about $3 per person a month, according to a new analysis.
Zealand touts efficacy, safety for petrelintide phase II obesity trial
Investors looking for midteen percentage weight loss findings in Zealand Pharma A/S’s phase II study of once-weekly amylin analogue petrelintide were clearly disappointed by the actual 10.7% mean body weight reduction, as shares (Copenhagen:ZEAL) fell 36% March 6. But from the company’s standpoint, the combination of efficacy and safety data from the Zupreme-1 study bode well for a phase III trial expected to start later this year.
GLP-1 Drugs Like Ozempic May Help Reduce Migraine Symptom Severity
Recent research has found that GLP-1s may reduce the need for emergency care in those with chronic migraine. Image Credit: Maskot/Getty Images
A recent study suggests that GLP-1 drugs, like Ozempic, may make people with chronic migraine less likely to require emergency care.
People using GLP-1s may be less likely to need new preventive migraine medications.
AAAAI: GLP-1 Receptor Agonists Linked to Reduction in Asthma Exacerbation Risk
FRIDAY, March 6, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with reduced asthma exacerbation risk among individuals with overweight or obesity, without diabetes, according to a study presented at the annual…
AAOS: GLP-1 Receptor Agonist Use Increases Five-Year Risk for Osteoporosis
FRIDAY, March 6, 2026 — Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia…
Some Patients Keep Weight off With Fewer GLP-1 Injections, Study Finds
FRIDAY, March 6, 2026 — Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study.The idea began when Dr. Mitch Biermann, an obesity and internal m…
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.